Outlook on the DNA Vaccine Global Market to 2030 –

DUBLIN, April 8, 2022 (GLOBE NEWSWIRE) — The “DNA Vaccines Market by Product Type, Type and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030” Report has been added ResearchAndMarkets.com Offer.

The global DNA vaccine market was valued at US$422.77 million in 2020 and is projected to reach US$774.43 million by 2030, growing at a CAGR of 6.3% from 2021-2030.

DNA vaccines are small, circular DNA plasmids that encode one or more protein antigens under the control of a promoter to elicit a specific immune response against disease. DNA vaccines are the third generation vaccines specifically designed to overcome the undesirable properties of traditional vaccines. The increasing susceptibility of the population to infectious diseases and the increase in the number of antibiotic-resistant pathogens have created the need for effective and inexpensive vaccines that would provide long-lasting immunity.

The major driving factors of DNA vaccines market include the increase in the prevalence of cancer and infectious diseases in humans and animals, as well as the increasing demand for DNA vaccines due to its advantages such as low risk of infection, easy transportation and stability at room temperature. In addition, the increase in the number of antibiotic-resistant pathogens has created the need for effective and inexpensive vaccines such as DNA vaccines, which would provide long-lasting immunity and would further fuel the growth of the DNA vaccine market.

However, the lack of immunogenicity associated with DNA vaccines may hamper the growth of the market. Additionally, the limited knowledge of human effects of DNA vaccines is expected to limit the growth of the market. In contrast, the development of novel vaccines utilizing DNA technology and high growth potential in untapped emerging markets are some factors that are expected to offer lucrative growth opportunities for players in the DNA vaccines market.

The global DNA vaccines market is segmented on the basis of product type, type, end-user and region to provide an in-depth assessment of the market. By product type, it is divided into Oncept, West Nile-Innovator and Apex-IHN. By type, the market is segmented into therapeutic vaccines and prophylactic vaccines. Based on the end user, it is categorized into Animal Hospitals, Animal Hospitals. Regionally, the market is only analyzed in North America as DNA vaccine products have not been approved in the other regions.

Main Benefits

  • The study provides an in-depth analysis of DNA Vaccine Market along with the current trends and future estimates to explain the upcoming investment pockets.
  • The report provides a comprehensive analysis of the factors driving and restraining the market growth.
  • A comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable stakeholders to capitalize on the prevailing market opportunities.
  • Comprehensive analyzes of the major segments of the industry help to understand the application and products of DNA Vaccines used around the world.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Main topics covered:

CHAPTER 1 INTRODUCTION

CHAPTER 2: SUMMARY

CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Important Findings
3.2.1. Top investment bags
3.2.2. The best winning strategies
3.3. Porter’s Five Forces Analysis
3.4. Top player positioning, 2020
3.5. market dynamics
3.5.1. driver
3.5.1.1. Increase in the prevalence of cancer and infectious diseases in humans and animals
3.5.1.2. Increasing demand for DNA vaccines
3.5.1.3. Increase in the number of antibiotic-resistant pathogens
3.5.2. limitations
3.5.2.1. Lack of immunogenicity associated with DNA vaccines
3.5.2.2. Limited knowledge of the effects of DNA vaccines on humans
3.5.3. occasions
3.5.3.1. Development of novel vaccines using DNA technology
3.5.3.2. High growth potential in untapped emerging markets
3.5.4. Impact Analysis
3.6. COVID-19 Impact Analysis on DNA Vaccine Market
3.7. Human DNA Vaccine

CHAPTER 4: DNA VACCINE MARKET BY PRODUCT TYPE
4.1. overview
4.1.1. Market size and forecast
4.2. concept
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market size and forecast by country
4.2.3. Market analysis by country
4.3. West Nile innovator
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market size and forecast by country
4.3.3. Market analysis by country
4.4. Apex-HIM
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market size and forecast by country
4.4.3. Market analysis by country

CHAPTER 5: DNA VACCINE MARKET BY TYPE
5.1. overview
5.1.1. Market size and forecast
5.2. Therapeutic Vaccines
5.2.1. Market size and forecast by country
5.2.2. Market analysis by country
5.3. Prophylactic Vaccines
5.3.1. Market size and forecast by country
5.3.2. Market analysis by country

CHAPTER 6: DNA VACCINE MARKET BY END USER
6.1. overview
6.1.1. Market size and forecast
6.2. animal clinics
6.2.1. Market size and forecast by country
6.2.2. Market analysis by country
6.3. animal clinics
6.3.1. Market size and forecast by country
6.3.2. Market analysis by country

CHAPTER 7: DNA VACCINE MARKET BY REGION

CHAPTER 8: COMPANY PROFILES
8.1. BOEHRINGER INGELHEIM GmbH (MERIAL)
8.1.1. company overview
8.1.2. Operational business areas
8.1.3. product portfolio
8.1.4. business performance
8.2. ELI-LILLY (NOVARTIS ANIMAL HEALTH)
8.2.1. company overview
8.2.2. Snapshot of the company
8.2.3. Operational business areas
8.2.4. product portfolio
8.2.5. business performance
8.3. GENEONE LIFE SCIENCE
8.3.1. company overview
8.3.2. Snapshot of the company
8.3.3. Operational business areas
8.3.4. product portfolio
8.4. GEOVAX LABS, INC.
8.4.1. company overview
8.4.2. Snapshot of the company
8.4.3. Operational business areas
8.4.4. product portfolio
8.4.5. business performance
8.5. INOVIO PHARMACEUTICALS (VGX ANIMAL HEALTH)
8.5.1. company overview
8.5.2. Snapshot of the company
8.5.3. Operational business areas
8.5.4. product portfolio
8.5.5. business performance
8.6. GENEXINE, INC.
8.6.1. company overview
8.6.2. Snapshot of the company
8.6.3. Operational business areas
8.6.4. product portfolio
8.7. VIATRIS INC. (ROTTAPHARM BIOTECH)
8.7.1. company overview
8.7.2. Snapshot of the company
8.7.3. Operational business areas
8.7.4. product portfolio
8.7.5. business performance
8.8. TAKARA HOLDINGS (TAKARA BIO)
8.8.1. company overview
8.8.2. Snapshot of the company
8.8.3. Operational business areas
8.8.4. product portfolio
8.8.5. business performance
8.9. ZOETIS INC. (FORT DODGE ANIMAL HEALTH)
8.9.1. company overview
8.9.2. Snapshot of the company
8.9.3. Operational business areas
8.9.4. product portfolio
8.9.5. business performance
8.10. CYDUS CADILA
8.10.1. company overview
8.10.2. Snapshot of the company
8.10.3. Operational business areas
8.10.4. product portfolio
8.10.5. business performance
8.10.6. Important strategic steps and developments

For more information about this report, see https://www.researchandmarkets.com/r/tqnu5l


        

Leave a Comment